Celebrex May Reduce Lung Cancer Threat in Ex-Smokers | The Fix
facebook twitter RSS
HOT TOPICS: Alcoholism  Addiction  AA  Cocaine  Heroin

Celebrex May Reduce Lung Cancer Threat in Ex-Smokers

Controversial arthritis drug cuts down on a crucial protein needed for tumor growth.


Only 15% still alive 5 years later.
Photo via thinkstockphotos

By Dirk Hanson


| Share

All smokers, both those who are abstinent and those still puffing away, harbor the same primal fear: A doctor identifies a “spot” on a lung after a routine chest X-ray.  The doctor arranges an appointment with a pulmonologist, who orders a CT scan, reviews it, and announces… it’s just a benign nodule. Nothing to worry about. That’s the happy scenario. The grim truth is that only about 15% of diagnosed lung cancer patients survive longer than 5 years. Lung cancer is a stone cold killer, and 85% of cases are smokers or former smokers. On Wednesday, a research team at the University of New Mexico announced that Celebrex, the controversial Cox-2 inhibitor used for the treatment of arthritis, may inhibit the growth of cells known to be precursors of lung cancer. Test subjects who took celecoxib had a 34% reduction in a protein called KI-67, which is an antigen necessary for cell proliferation, and is used as a marker for monitoring cell growth. In the case of breast and prostate cancer, the fraction of KI-67-positive cells in a tumor has proven to be a useful tool for determining how advanced a cancer is. The team found that the placebo group had a 3.8% increase over the same test period.

A lot more testing needs to be done. One potential problem: Celebrex increases the risk of cardiovascular disease and stroke, so future clinical studies will be limited to smokers with no other cardiovascular risk factors.

Rehabilitation Directories

Most Popular
Sober Living
Hey You!

“Listen,” you tell the cop. “I know I passed the fucking test, and you know I passed the fucking test, so can I get back into my truck and drive home now?”

the fix tv